RedHill Biopharma Shares Outstanding History (RDHL)
RedHill Biopharma reported 50.92B shares outstanding at the end of fiscal 2025.
View full RedHill Biopharma company overviewRedHill Biopharma annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 50.92B | 38.02B | +294.76% |
| 2024 | 2024-12-31 | 12.90B | 153.0M | +1.20% |
| 2023 | 2023-12-31 | 12.75B | 11.57B | +980.50% |
| 2022 | 2022-12-31 | 1.18B | 652.9M | +123.92% |
| 2021 | 2021-12-31 | 526.8M | 142.9M | +37.21% |
| 2020 | 2020-12-31 | 384.0M | 31.3M | +8.87% |
| 2019 | 2019-12-31 | 352.7M | 69.0M | +24.33% |
| 2018 | 2018-12-31 | 283.7M | 71.0M | +33.36% |
| 2017 | 2017-12-31 | 212.7M | — | — |
RedHill Biopharma quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 50.92B | 38.02B | +294.76% |
| Q2 2025 | 2025-06-30 | 23.16B | — | — |
| Q4 2024 | 2024-12-31 | 12.90B | 153.0M | +1.20% |
| Q4 2023 | 2023-12-31 | 12.75B | 11.57B | +980.50% |
| Q4 2022 | 2022-12-31 | 1.18B | 652.9M | +123.92% |
| Q4 2021 | 2021-12-31 | 526.8M | 142.9M | +37.21% |
| Q4 2020 | 2020-12-31 | 384.0M | 31.3M | +8.87% |
| Q4 2019 | 2019-12-31 | 352.7M | 69.0M | +24.33% |
| Q4 2018 | 2018-12-31 | 283.7M | 71.0M | +33.36% |
| Q4 2017 | 2017-12-31 | 212.7M | 0 | 0.00% |
| Q4 2016 | 2016-12-31 | 212.7M | — | — |
RedHill Biopharma shares outstanding trends
Over the last five fiscal years, RedHill Biopharma's shares outstanding moved from 384.0M to 50.92B, a change of 50.54B. The latest reported quarter, Q4 2025, shows 50.92B.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RedHill Biopharma source filings ↗